BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 4, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference

-Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.- BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 29, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating

BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 28, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were

- Companies Plan to Submit Biologics License Application Later This Year - - Seattle Genetics to Hold Conference Call Today at 9:00 a.m. EDT - BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Mar. 28, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc.

BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 27, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data highlights from six presentations showcasing technology advances in the company’s antibody-drug conjugate (ADC) platform and an immuno-oncology program at the American Association for Cancer

BOTHELL, Wash. --(BUSINESS WIRE)--Mar. 5, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m. Eastern Time . The presentation will be webcast live and available

BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 11, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited , received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include

-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $476.9 Million in 2018, Including $132.1 Million in the Fourth Quarter- -ADCETRIS Approved by FDA in Combination with Chemotherapy for Frontline CD30-Expressing PTCL- -Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic

BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 6, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time . The presentation will be webcast live and

BOTHELL, Wash. --(BUSINESS WIRE)--Jan. 22, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will